

DAFTAR PUSTAKA

1. Joint United Nations Programme on HIV/AIDS. *UNAIDS DATA*. Switzerland, 2019.
2. Ditjen P2P Kementerian Kesehatan RI. Laporan Perkembangan HIV/AIDS dan Penyakit Menular Seksual Triwulan II Tahun 2019. 2019; 1–163.
3. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter Study. *Neurology* 2010; 75: 2087–2096.
4. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: The Hawaii aging with HIV-1 cohort. *Neurology* 2004; 63: 822–827.
5. Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a South Asian population - Contextual application of the 2007 criteria. *BMJ Open*; 2. Epub ahead of print 2012. DOI: 10.1136/bmjopen-2011-000662.
6. Stern Y, McDermott MP, Albert S, et al. Factors associated with incident human immunodeficiency virus-dementia. *Arch Neurol* 2001; 58: 473–479.
7. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695–699.
8. Husein N, Lumempouw S, Ramli Y. MoCA-INA untuk skrining gangguan fungsi kognitif. *2010 Neurona*; 27.
9. Clos TW Du. Function of C-reactive protein. 2000; 274–278.
10. Schouten J, Su T, Wit FW, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. *Aids* 2016; 30: 1027–1038.
11. Watanabe Y, Kitamura K, Nakamura K, et al. Elevated C-Reactive Protein is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST). *Dement Geriatr Cogn Dis Extra* 2016; 6: 10–19.
12. Rubin LH, Benning L, Keating SM, et al. Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study. *J Neurovirol* 2018; 24: 41–51.
13. Burdo TH, Weiffenbach A, Woods SP, et al. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. *Aids* 2013; 27: 1387–1395.
14. Waggoner JJ, Gresh L, Vargas MJ, et al. Monocyte Activation Is Associated With Worse Cognitive Performance in HIV-Infected Women With Virologic Suppression. 2016; 1–26.
15. Nasronudin. HIV & AIDS :Pendekatan Biologi Molekuler, Klinis dan Sosial. *Surabaya Airlangga Univ Press* 2014; Edisi ke 2.
16. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. *Lancet* 2014; 384: 258–271.
17. Bozzuto. From bench to bedside and to health policies: Ethics in translational research. *Clin Ter* 2011; 162: 51–59.
18. French MA. Immunological Responses to Antiretroviral Therapy Reconstitution of the Immune System Following Suppression of HIV

- Replication by ART. 2014; 1–9.
19. Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: A review of current methods. *Clin Infect Dis* 2013; 57: 712–718.
 20. Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV (PNPK-HIV 2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/90/2019. 2019; 220.
 21. AIDSinfo. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. *Dep Heal Hum Serv* 2018; 298.
 22. Rao MRM, Gopal SD. Case Study C-Reactive Protein - A critical Review. 2015; 4: 55–61.
 23. Ankara. Editorial [Editörden] C-Reactive protein vs . high - sensitivity C - reactive protein : What is the difference ? 2014; 39: 43–44.
 24. Yogyakarta SH. C-reactive protein (CRP) Vs high-sensitivity CRP (hs-CRP). 2018; 4–6.
 25. Strang F, Schunkert H. C-Reactive Protein and Coronary Heart Disease : All Said — Is Not It? 2014. Epub ahead of print 2014. DOI: 10.1155/2014/757123.
 26. McFadyen JD, Kiefer J, Braig D, et al. Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of C-reactive protein and its conformational changes. *Front Immunol*; 9. Epub ahead of print 2018. DOI: 10.3389/fimmu.2018.01351.
 27. Yasojima K, Schwab C, McGeer EG, et al. Human neurons generate C-reactive protein and amyloid P: Upregulation in Alzheimer’s disease. *Brain Res* 2000; 887: 80–89.
 28. Calabro P, Chang DW, Willerson JT, et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: Linking obesity to vascular inflammation [1]. *J Am Coll Cardiol* 2005; 46: 1112–1113.
 29. Kushner I, Samols D. A Unifying Biologic Explanation for “ High-Sensitivity ” C-Reactive Protein and “ Low-Grade ” Inflammation. 2010; 62: 442–446.
 30. Aguiar FJB, Ferreira-Júnior M, Sales MM, et al. C-reactive protein: clinical applications and proposals for a rational use. *Rev Assoc Med Bras* 2013; 59: 85–92.
 31. Clyne B, Olshaker JS. The C-reactive protein. *J Emerg Med* 1999; 17: 1019–1025.
 32. Cem Gabay IK. Acute-Phase Proteins and other Systemic responses to inflammation. *New Engl J Med Mech*.
 33. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. *J Acquir Immune Defic Syndr* 2003; 32: 210–214.
 34. Lau B, Sharrett R, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. *Arch Intern Med* 2006; 166: 64–70.
 35. Wijoto PT. *Gangguan Neurobehaviour. Buku Ajar Ilmu Penyakit Saraf*. Surabaya: Airlangga University Press, 2011.
 36. Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: The DSM-5 approach. *Nat Rev Neurol* 2014; 10: 634–642.

37. Odawara T. [Diagnostic criteria for dementia with Lewy bodies]. *Nihon Rinsho* 2011; 69 Suppl 1: 346–349.
38. Lori F. Treating HIV/AIDS by reducing immune system activation: The paradox of immune deficiency and immune hyperactivation. *Curr Opin HIV AIDS* 2008; 3: 99–103.
39. Hatano H. Immune activation and HIV persistence: Considerations for novel therapeutic interventions. *Curr Opin HIV AIDS* 2013; 8: 211–216.
40. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. *Curr Opin HIV AIDS* 2010; 5: 498–503.
41. Boulware DR, Hullsiek KH, Puroon CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. *J Infect Dis* 2011; 203: 1637–1646.
42. Bora A, Mohien CU, Chaerkady R, et al. Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. *J Neurovirol* 2014; 20: 457–465.
43. Grant I. Neurocognitive disturbances in HIV. 2008; 20: 33–47.
44. Rizzi L, Marques FC, Rosset I, et al. C-Reactive Protein and Cognition Are Unrelated to Leukoaraiosis. 2014. Epub ahead of print 2014. DOI: 10.1155/2014/121679.
45. Yaffe K, Lindquist K, Penninx BW, et al. and white elders. 2003; 1–5.
46. Schouten J, Su T, Wit FW, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. Epub ahead of print 2016. DOI: 10.1097/QAD.0000000000001017.
47. Rubin LH, Benning L, Keating SM, et al. Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV : a longitudinal study.
48. Clifford DB, Franklin DR, Woods SP, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. 2010; 2087–2096.
49. Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria. 2012; 1–6.
50. Estiasari R, Imran J, Lastri DN, et al. Cognitive impairment among Indonesia HIV naïve patients. *Neurol Asia* 2015; 20: 155–160.
51. Hasbun R, Eraso J, Ramireddy S, et al. Utility of the Montreal Cognitive Assessment Test. *J AIDS Clin Res*; 3. Epub ahead of print 2013. DOI: 10.4172/2155-6113.1000186.Screening.
52. Mattson NJHa and MP. Calcium_Dysregulation_and_Neuronal_Apoptosis_by.5.pdf.
53. Aversa TGD, Eugenin EA, Berman JW. Review NeuroAIDS : Contributions of the Human Immunodeficiency Virus-1 Proteins Tat and gp120 as Well as CD40 to Microglial Activation. 2005; 446: 436–446.
54. Ransohoff RM. Snip-snip, kill-kill: Truncated SDF-1 and HIV-associated neurodegeneration. *Nat Neurosci* 2003; 6: 1009–1011.
55. Manuscript A. Monocyte / macrophages and their role in HIV

- neuropathogenesis. 2014; 254: 102–113.
56. Banks SHWA. Role of the Immune System in HIV-associated Neuroinflammation and Neurocognitive Implications Suzi. *NIH Public Access Author* 2016; 1–12.
 57. Vera JH, Cole JH, Boasso A, et al. Neuroinflammation in treated HIV-positive individuals. 2016; 1425–1432.
 58. Eugenin EA. HIV infection of human astrocytes disrupts blood brain barrier integrity by a gap junction dependent mechanism Eliseo. 2011; 31: 9456–9465.
 59. Monocytes H, Hill C, Hill C, et al. HIV-1 Infection Induces Interleukin-1^α Production via TLR8 Protein-dependent and NLRP3 Inflammasome Mechanisms in. 2014; 289: 21716–21726.
 60. Chattergoon MA, Latanich R, Quinn J, et al. HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon. 10. Epub ahead of print 2014. DOI: 10.1371/journal.ppat.1004082.
 61. Aounallah M, Dagenais-lussier X, El-far M, et al. Cytokine & Growth Factor Reviews Current topics in HIV pathogenesis , part 2 : In fl ammation drives a Warburg-like effect on the metabolism of HIV-infected subjects. *Cytokine Growth Factor Rev.* Epub ahead of print 2016. DOI: 10.1016/j.cytogfr.2016.01.001.
 62. Cells DCDT, Galloway NLK, Doitsh G, et al. Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue- Report Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells. 2015; 1–9.
 63. Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. *J Infect Dis* 2013; 207: 1703–1712.
 64. Calza L, Magistrelli E, Danese I, et al. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz. *Curr HIV Res* 2015; 14: 61–70.
 65. Slaats J, Oever J, Veerdonk FL Van De, et al. IL-1 β / IL-6 / CRP and IL-18 / ferritin : Distinct Inflammatory Programs in Infections. 2016; 1–13.
 66. Colafrancesco S, Priori R, Alessandri C, et al. IL-18 Serum Level in Adult Onset Still ' s Disease : A Marker of Disease Activity. 2012. Epub ahead of print 2012. DOI: 10.1155/2012/156890.
 67. Shine B, Beer FC De, Pepys MB. Solid phase radioimm ~ noassays C-reactive protein for human. 1981; 117: 13–23.
 68. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease . Find the latest version : 1993; 91: 1351–1357.
 69. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder - Pathogenesis and prospects for treatment. *Nat Rev Neurol* 2016; 12: 234–248.
 70. Elbirt D, Mahlab-Guri K, Bezalel-Rosenberg S, et al. HIV-associated neurocognitive disorders (HAND). *Isr Med Assoc J* 2015; 17: 54–9.

71. Paulus sugianto, A. Rizal ganiem B muni. Modul Neuroinfeksi Kelompok. *Neurol Clin* 2019; 330–336.
72. Mogambery JC, Dawood H, Wilson D, et al. HIV-associated neurocognitive disorder in a KwaZulu-Natal HIV clinic: A prospective study. *South Afr J HIV Med* 2017; 18: 1–5.
73. Mccombe J, Vivithanaporn P, Gill M, et al. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. *HIV Med* 2013; 14: 99–107.
74. Lawler K, Mosepele M, Ratcliffe S, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: A pilot study. *J Int AIDS Soc* 2010; 13: 1–9.
75. Glowicz. HHS Public Access. *Physiol Behav* 2017; 176: 139–148.
76. Catroppa C, Anderson V. Developmental Neuropsychology Children ' s Attentional Skills 2 Years Post-Traumatic Brain Injury. 2010; 37–41.
77. Tymchuk S, Gomez D, Koenig N, et al. Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS. *Can J Psychiatry* 2018; 63: 329–336.
78. Cross S, Önen N, Gase A, et al. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. *J Neuroimmune Pharmacol* 2013; 8: 1114–1122.
79. Subica A, Fowler J, Elhai J, et al. Factor structure and diagnostic validity of the Beck Depression Inventory-II with adult clinical inpatients: comparison to a gold-standard diagnostic interview. *Psychol Assess* 2014; 26: 1106–15.
80. Tedaldi EM, Minniti NL, Fischer T. Review Article HIV-Associated Neurocognitive Disorders : The Relationship of HIV Infection with Physical and Social Comorbidities. 2015. Epub ahead of print 2015. DOI: 10.1155/2015/641913.
81. Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. *HIV Med* 2013; 14: 136–144.
82. Okafor CN, Kelso NE, Bryant V, et al. Body mass index, inflammatory biomarkers and neurocognitive impairment in HIV-infected persons. *Psychol Health Med* 2017; 22: 289–302.
83. Kivimaki M, Shipley MJ, Marmot MG, et al. EU weighs bank capital rules. 2010; 5608.
84. Shen C, Bao WM, Yang BJ, et al. Cognitive deficits in patients with brain tumor. *Chin Med J (Engl)* 2012; 125: 2610–2617.
85. Sun J-H, Tan L, Yu J-T. Post-stroke cognitive impairment: epidemiology, mechanisms and management. *Ann Transl Med* 2014; 2: 80.
86. Levine AJ, Hinkin CH, Ando K, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. *J Clin Exp Neuropsychol* 2008; 30: 836–843.
87. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders A. 2015; 69: 1789–1799.
88. Nadia Husein, Silvia Lumempouw, Yetty Ramli H. Montreal Cognitive Assessment versi Indonesia (MoCA-INA) untuk skrining gangguan fungsi kognitif Nadia. 27.
89. María J, Garrido F, Fernández ML, et al. Cognitive Performance in Men and

- Women Infected with HIV-1. 2013.
90. McCutchan JA, Marquie-Beck JA, FitzSimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. *Neurology* 2012; 78: 485–492.
 91. Ku NS, Lee Y, Ahn JY, et al. HIV-associated neurocognitive disorder in HIV-infected Koreans : the Korean NeuroAIDS Project. 2014; 470–477.